1. Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes
- Author
-
Vladimir S. Prassolov, Carol Stocking, Dmitry Konovalov, T D Lebedev, Pavel Spirin, Maria Suntsova, Anton Buzdin, Alexander Roumiantsev, Elmira Vagapova, Maxim Sorokin, Olga Astashkova, Petr M. Rubtsov, Alesya Mikheeva, and Uliana Vladimirova
- Subjects
MAPK/ERK pathway ,Cancer Research ,Cabozantinib ,Cell Survival ,medicine.medical_treatment ,Biology ,Article ,Paediatric cancer ,chemistry.chemical_compound ,Neuroblastoma ,Cell Line, Tumor ,Nerve Growth Factor ,Genetics ,medicine ,Cancer genomics ,Humans ,Molecular Biology ,Erythropoietin ,Protein Kinase Inhibitors ,Cell Proliferation ,Neoplasm Staging ,Crizotinib ,Growth factor ,medicine.disease ,Survival Analysis ,Axitinib ,Dasatinib ,Gene Expression Regulation, Neoplastic ,chemistry ,Drug Resistance, Neoplasm ,Cancer cell ,Mutation ,Cancer research ,medicine.drug ,Signal Transduction - Abstract
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells’ ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the expression of 48 growth factor-related genes in 1189 NB tumors, we have developed a model for NB patient survival prediction. This model discriminates between stage 4 NB tumors with favorable outcomes (>80% overall survival) and very poor outcomes (
- Published
- 2021